Komori
Mitsubishi Chemical Group (4188) · InitiativeAgreement to terminate the supply agreement and recognition of advance payments as revenue

COVID-19 vaccine development

First written in FY2020. 4 of 9 entries say "Advanced", first in FY2021. Latest entry: FY2024-Q3.

9entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020AdvancedFY2022-Q2 – FY2022DroppedFY2023-Q3 – FY2024-Q32020: 120202021: 320212022: 320222023: 120232024: 1
Same theme, other companies
Development and termination of Mitsubishi Tanabe Pharma Corporation's COVID-19 vaccine businessA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3Agreement to terminate the supply agreement and recognition of advance payments as revenueAnnual report

    「Of the ¥15.53 billion in advance payments received in connection with the healthcare segment's COVID-19 vaccine supply agreement, the requirements for recognizing the amount as a contract liability were no longer met at the end of the previous fiscal year, so it had been reclassified from advance payments to another liability account. During the cumulative third quarter of the current fiscal year, the Company agreed with the counterparty to terminate the agreement, and the portion recorded under other liabilities became non-refundable under that agreement. The liability was therefore derecognized and other operating income was recognized.」

    After the COVID-19 vaccine business ended, the Company agreed to terminate the supply agreement and recognized the ¥15.530 billion in advance payments that no longer required repayment as other operating income.
  2. FY2023-Q3DroppedAnnual report

    「However, the environment surrounding COVID-19 has changed significantly. After comprehensively considering global demand and market conditions for COVID-19 vaccines at present, as well as the company's challenges in transitioning to commercial-scale production, it was concluded that commercialization of this VLP vaccine should be abandoned. It was also determined that, given the difficulty of continuing to make further investments in the future commercialization of the company's development products, the business should be exited and liquidation proceedings initiated.」

    The Company decided to abandon the commercialization of Medicago's plant-derived VLP vaccine, withdraw from the business and proceed with liquidation.
  3. FY2023-Q2SoftenedAnnual report

    「However, challenges have arisen in commercializing the COVID-19 vaccine in the healthcare segment.」

    Although COVID-19 vaccine development continued, the emergence of challenges to commercialization was cited as a reason for lowering the earnings forecast for the second half.
  4. FY2022AdvancedAnnual report

    「Medicago, a consolidated subsidiary, obtained approval in Canada in February 2022 for MT-2766, a plant-derived Virus Like Particle vaccine being developed to prevent COVID-19 under the development code MT-2766. It became the world's first plant-derived COVID-19 vaccine.」

    MT-2766 received approval in Canada in February 2022, advancing from the clinical trial stage to the approval stage.
  5. FY2022-Q3AdvancedAnnual report

    「In addition, based on favorable results from the Phase 3 portion of the Phase 2/3 clinical trial conducted in Canada and elsewhere, Medicago submitted an application for approval in Canada in December 2021.」

    For the MT-2766 COVID-19 vaccine, favorable results from the Phase 3 portion in Canada and elsewhere led to the stage of submitting an application for approval in Canada in December 2021.
  6. FY2022-Q2AdvancedAnnual report

    「Mitsubishi Tanabe Pharma Corporation began a Phase 1/2 clinical trial in Japan in October 2021 for MT-2766, a plant-derived virus-like particle (VLP) vaccine being developed by its consolidated subsidiary Medicago Inc. to prevent COVID-19. Medicago began the Phase 3 portion of a Phase 2/3 clinical trial for the vaccine in Canada and elsewhere in March 2021.」

    For the MT-2766 COVID-19 vaccine, the Phase 3 portion of the Phase 2/3 clinical trial continued in Canada and elsewhere, while a Phase 1/2 clinical trial also began in Japan in October 2021.
  7. FY2022-Q1RestatedAnnual report

    「Core operating profit decreased due to higher R&D expenses for the COVID-19 vaccine, among other factors.」

    COVID-19 vaccine development continued, and higher R&D expenses became a factor behind the decline in healthcare earnings. This filing does not describe the achievement of a new development stage.
  8. FY2021AdvancedAnnual report

    「Medicago Inc., a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation headquartered in Quebec City, Canada, began the Phase 3 portion of a Phase 2/3 clinical trial in Canada and the United States in March 2021 for MT-2766, a plant-derived virus-like particle (VLP) vaccine intended to prevent COVID-19.」

    COVID-19 vaccine development advanced to the start of the Phase 3 portion of the Phase 2/3 clinical trial. The construction of new vaccine manufacturing facilities was also reported as capital expenditure.
  9. FY2020First statedAnnual report

    「COVID-19 is a serious social issue that threatens the sustainability of people, society and the planet. Mitsubishi Tanabe Pharma Corporation's Canadian subsidiary is already working on vaccine development, and the Group will continue to pursue ways in which it can contribute.」

    The Company first explicitly disclosed vaccine development by Mitsubishi Tanabe Pharma's Canadian subsidiary as a contribution to addressing COVID-19. It also described the construction of vaccine manufacturing facilities and the advancement of development.
Moved together

"Portfolio and Structural Reform of the Petrochemicals Business" moved the same way as this thread, in the same document, in 4 of its 9 moves.

443333★123456
  1. ★This thread
  2. 1Portfolio and Structural Reform of the Petrochemicals Business4×
  3. 2Improving profitability through cost reductions and asset reduction4×
  4. 3Earnings volatility arising from demand, market conditions, raw material prices, foreign exchange and supply constraints3×
  5. 4Funding risks from interest-bearing debt, interest rates and credit-rating downgrades3×
  6. 5Improvement of the net debt-to-equity ratio to 1.0 or below under APTSIS253×
  7. 6Strategic investments, including capital expenditure and M&A, in growth businesses3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Mitsubishi Chemical Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.